drugset / Trial / NCT00489840

Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate

NCT00489840

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Investigation to evaluate Anecortave Acetate in the treatment of chronic central serous chorioretinopathy

Timeline

Start
2007-05
Primary completion
2010-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Anecortave Acetate Small molecule 15 mg Other